CSCI vs. MRSN, RNXT, AADI, ATRA, BDRX, KRON, CNTB, AKTX, AVTX, and KPTI
Should you be buying COSCIENS Biopharma stock or one of its competitors? The main competitors of COSCIENS Biopharma include Mersana Therapeutics (MRSN), RenovoRx (RNXT), Aadi Bioscience (AADI), Atara Biotherapeutics (ATRA), Biodexa Pharmaceuticals (BDRX), Kronos Bio (KRON), Connect Biopharma (CNTB), Akari Therapeutics (AKTX), Avalo Therapeutics (AVTX), and Karyopharm Therapeutics (KPTI). These companies are all part of the "pharmaceutical products" industry.
COSCIENS Biopharma vs.
Mersana Therapeutics (NASDAQ:MRSN) and COSCIENS Biopharma (NASDAQ:CSCI) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, risk, valuation, earnings, community ranking, institutional ownership, analyst recommendations, profitability and media sentiment.
In the previous week, COSCIENS Biopharma had 7 more articles in the media than Mersana Therapeutics. MarketBeat recorded 9 mentions for COSCIENS Biopharma and 2 mentions for Mersana Therapeutics. COSCIENS Biopharma's average media sentiment score of 0.47 beat Mersana Therapeutics' score of 0.44 indicating that COSCIENS Biopharma is being referred to more favorably in the news media.
Mersana Therapeutics has a beta of 1.32, indicating that its stock price is 32% more volatile than the S&P 500. Comparatively, COSCIENS Biopharma has a beta of 0.89, indicating that its stock price is 11% less volatile than the S&P 500.
Mersana Therapeutics presently has a consensus target price of $5.20, indicating a potential upside of 1,389.97%. Given Mersana Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Mersana Therapeutics is more favorable than COSCIENS Biopharma.
COSCIENS Biopharma has lower revenue, but higher earnings than Mersana Therapeutics. COSCIENS Biopharma is trading at a lower price-to-earnings ratio than Mersana Therapeutics, indicating that it is currently the more affordable of the two stocks.
Mersana Therapeutics received 256 more outperform votes than COSCIENS Biopharma when rated by MarketBeat users.
Mersana Therapeutics has a net margin of -214.20% compared to COSCIENS Biopharma's net margin of -428.43%. COSCIENS Biopharma's return on equity of -95.93% beat Mersana Therapeutics' return on equity.
93.9% of Mersana Therapeutics shares are held by institutional investors. Comparatively, 0.7% of COSCIENS Biopharma shares are held by institutional investors. 13.0% of Mersana Therapeutics shares are held by company insiders. Comparatively, 0.1% of COSCIENS Biopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Summary
Mersana Therapeutics beats COSCIENS Biopharma on 13 of the 18 factors compared between the two stocks.
Get COSCIENS Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for CSCI and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
COSCIENS Biopharma Competitors List
Related Companies and Tools
This page (NASDAQ:CSCI) was last updated on 5/30/2025 by MarketBeat.com Staff
